This is arguably the single most important number for reading any hot flash treatment claim.

In hormone therapy trials, women given a placebo pill still had a 57.7 percent reduction in hot flushes from baseline. In one analysis of an approved drug's own registration trials, about 79 percent of the average improvement in flash frequency was accounted for by the placebo response, leaving a true drug effect of at most about 21 percent. That means a product advertised as reducing hot flashes by 60 percent, with no placebo-controlled comparison, is very likely riding this same natural effect, not proving the product itself works.

What to know about this answer

There is no real scientific disagreement that the placebo response in hot flash trials is large. The practical tension is between how rigorously regulated drugs are tested, blinded and placebo-controlled, versus how many supplement and wellness products are marketed, using before-after testimonials and short unblinded trials.

What the research shows, and which source each finding rests on

In the Cochrane meta-analysis of oral hormone therapy trials, women randomized to placebo had a 57.7 percent reduction in hot flushes from baseline to end of study (95 percent CI 45.1-67.7)

A[1]

In the paroxetine registration trials, a meta-analysis found 79 percent of the mean treatment response for hot flash frequency was accounted for by placebo response (68 percent for severity), leaving a true drug effect of at most 21 percent of the observed change

A[2]

Concrete placebo-arm numbers from landmark trials: placebo reduced vasomotor symptoms 28.6 percent in one head-to-head estradiol-versus-venlafaxine trial, 29 percent in a gabapentin trial, about 36 percent of women achieved a 50-percent-plus reduction on placebo in an escitalopram trial, and -3.5 episodes/day in a recent elinzanetant trial's placebo arm

B[3]B[4]B[5]B[6]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Unblinded or short trials cannot distinguish a real effect from placebo

The Cochrane review authors, in their explicit methodological warning

Any purported vasomotor symptom therapy must be tested blinded against placebo, because of the large placebo effect and because symptoms fluctuate during menopause and often decline naturally afterward, so an unblinded before-after study, or even a short blinded one as the paroxetine analysis shows, can make an inert product look effective.

A[1]A[2]

What would settle it: Any specific product claim would be settled by a blinded, placebo-controlled trial of adequate length and size, which most marketed hot flash products lack.

What is really going on here

  1. Was this treatment tested against placebo, and what did the placebo arm do? Placebo arms in vasomotor symptom trials improve 30 to 58 percent, so a before-after percent change alone is riding the placebo response plus natural symptom decline.
  2. Is the percent reduction from baseline, or versus placebo? The placebo-adjusted number is the drug's real contribution.

Questions for your doctor

  1. Was this treatment tested in a blinded, placebo-controlled trial, and for how long?
  2. What is the placebo-adjusted effect size, not just the before-after change?
  3. If a benefit fades after a few months, could that be the placebo effect wearing off rather than the treatment failing?
  4. What independent, peer-reviewed evidence exists for this specific product or drug?

Questions with no answer yet

Why is the placebo response in hot flash trials so unusually large, 30 to 58 percent, compared with many other medical conditions, and would understanding that mechanism suggest better ways to design future trials?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The size of the placebo response is documented repeatedly and consistently, but the underlying mechanism for why vasomotor symptoms specifically show such a large placebo response is not explained beyond noting that symptoms naturally fluctuate and can decline over time regardless of treatment.

What would test it: Mechanistic research into what drives expectation effects and natural fluctuation specifically in hot flash symptom reporting, which could inform trial design standards.

Does the size of the placebo response differ depending on how a treatment is delivered, a pill versus a cream versus a device, and if so, could that explain why some product categories generate more dramatic testimonials than others?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Placebo response magnitudes are reported across pill-based trials and a hypnosis trial's attention-control arm, but there is no systematic comparison of placebo response size across delivery methods to test whether the route itself affects the size of the placebo effect.

What would test it: A systematic comparison of placebo-arm response sizes across different delivery methods within otherwise comparable trial designs.

If a supplement or wellness product has never been tested against placebo at all, is there any way for a consumer to estimate how much of its reported benefit is likely to be placebo, short of demanding a proper trial?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The guiding principle is that any purported therapy must be tested blinded against placebo because of the size of the effect, without offering a validated shortcut or estimation method for products that have never been tested this way at all.

What would test it: This is less a research gap than a call for mandatory blinded placebo-controlled testing before efficacy claims are marketed. No substitute estimation method currently exists.

Sources

  1. 1.Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.MacLennan AH et al., Cochrane Database Syst Rev 2004 · Systematic review or guideline
  2. 2.Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis.Rhodes JR, Alldredge CT, Elkins GR, Front Psychiatry 2023 · Systematic review or guideline
  3. 3.Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.Joffe H et al., JAMA Intern Med 2014 · Randomised trial
  4. 4.Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.Guttuso T et al., Obstet Gynecol 2003 · Randomised trial
  5. 5.Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.Freeman EW et al., JAMA 2011 · Randomised trial
  6. 6.Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.Panay N et al., JAMA Intern Med 2025 · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides